Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.7312 - Towerbrook/ Independent Clinical Services Group Limited

SECTION 1.2

Description of the concentration

The notified concentration involves the proposed acquisition by TowerBrook Investors Limited (“TowerBrook”) of sole control of Independent Clinical Services Group Limited (“ICS”) (the “Proposed Transaction”).

The areas of activities of the undertakings concerned by the Proposed Transaction are as follows:

(a) TowerBrook – TowerBrook is the ultimate general partner of certain affiliates of funds managed by TowerBrook Capital Partners L.P. (“TowerBrook Capital Partners”). Founded in 2005, TowerBrook Capital Partners is a global private equity firm. TowerBrook Capital Partners seeks to invest in large and middle market companies in Europe and North America.

(b) ICS – ICS is a provider of health, life sciences and social care staffing and services to the UK health sector.

As a result of the Proposed Transaction, funds managed by TowerBrook will acquire sole control of ICS within the meaning of Article 3(1)(b) of the EU Merger Regulation.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.